Abstract
Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.
| Original language | English |
|---|---|
| Pages (from-to) | 217-230 |
| Number of pages | 14 |
| Journal | Journal of Biomedicine and Biotechnology |
| Volume | 2003 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 29 Oct 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Genetics
- Applied Microbiology and Biotechnology
Cite this
Postgenomics : Proteomics and Bioinformatics in Cancer Research. / Bensmail, Halima; Haoudi, Abdelali.
In: Journal of Biomedicine and Biotechnology, Vol. 2003, No. 4, 29.10.2003, p. 217-230.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Postgenomics
T2 - Proteomics and Bioinformatics in Cancer Research
AU - Bensmail, Halima
AU - Haoudi, Abdelali
PY - 2003/10/29
Y1 - 2003/10/29
N2 - Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.
AB - Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.
UR - http://www.scopus.com/inward/record.url?scp=0347362472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0347362472&partnerID=8YFLogxK
U2 - 10.1155/S1110724303209207
DO - 10.1155/S1110724303209207
M3 - Article
VL - 2003
SP - 217
EP - 230
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
IS - 4
ER -